Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?

Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled “Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer” published on Journal of Clinical Oncology.

Authors: Robbert-Jan Gielen, Sylvia Adams, Jochen K. Lennerz, Priyanka Sharma, Sibylle Loibl, Erin Reardon, Gabe Sonke, Sabine Linn, Suzette Delaloge, Denis Lacombe, Tim Robinson, Sunil Badve, Miguel Martin, Justin M. Balko, Michail Ignatiadis, Giuseppe Curigliano, Antonio C. Wolff, Elizabeth A. Mittendorf, Sherene Loi, Lajos Pusztai, Sara M. Tolaney and Roberto Salgado

“Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?

If you have 20 minutes for a read this week, make sure not to miss this Journal of Clinical Oncology commentary by Marleen Kok et al, full of thought provoking reflections on the path forward in treating TNBC.”

Quoting Paolo Tarantino’s post Marleen Kok added:

“Thanks for highlighting our Commentary paper on challenges in treatment of TNBC.”

Sources: Paolo Tarantino/X and Marleen Kok/X

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.

Marleen Kok is a medical oncologist and associate professor in translational cancer research at the Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands, where she leads the breast cancer immunotherapy program and a translational breast cancer immunology laboratory. She is working at the forefront of innovative immunotherapy trials. The mission of her clinical and translational team is to improve immunomodulatory treatments for breast cancer patients. She is the recipient of The 2023 Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Grant to investigate cancer-immune interactions in-depth in patients with TNBC in the context of anti-PD1 treatment.